A Phase I trial has started in Sudan to test a therapeutic vaccine against post kala-azar dermal leishmaniasis (PKDL), a complication of the visceral form of the parasitic disease. Leishmaniasis is found in parts of the tropics, subtropics and southern Europe, with Sudan having the highest number of PKDL cases in the world.
Infectious Disease Research Institute's vaccine candidate will be tested for safety and its ability to induce an immune response against...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
